Electronic Health Record Alert With Heart Failure Risk and Sodium Glucose Cotransporter 2 Inhibitor Prescriptions in Diabetes: A Randomized Clinical Trial
Authors' conclusion
In a single-center trial with low overall SGLT2i use, an EHR alert incorporating HF risk information significantly increased SGLT2i prescriptions and NP testing although the absolute rates were low.
Study context
- Population
- Patients with T2D and no history of heart failure (HF) or SGLT2i use, general and subspecialty internal medicine and family medicine outpatient clinics; median age 75 years, 45% women, 23% Black
- Participants
- 1,524 patients189 outpatient clinics
- Comparison
- Electronic health record (EHR) alert with HF risk vs usual care
- EHR alertn = 780
- Usual caren = 744reference
- Primary endpoint
- Proportion of SGLT2i prescriptions
- Follow-up
- Within 30 days
Methodological detailspragmatic, single-centre, randomization at provider level, Enrolled September 28, 2021 to April 29, 2022
- Pragmatic
- Single-centre
- Randomization at provider level
- Enrolled September 28, 2021 to April 29, 2022
Primary result
As reported in the abstract
SGLT2i prescriptions
P = 0.009
Further findings
Natriuretic peptide testing · within 90 days
P = 0.02
Original publication
Electronic Health Record Alert With Heart Failure Risk and Sodium Glucose Cotransporter 2 Inhibitor Prescriptions in Diabetes: A Randomized Clinical Trial. J Diabetes Sci Technol. Published 10 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →